BREAKOUT STOCK ALERT UPDATE
$EYPT - EyePoint Pharmaceuticals, Inc. - Common Stock Status Alert: Deficient
Initial Alert Price: $4.78
Price High: $6.23
% Gains/Losses: 30.33%
(+19.33% More Than Expected)
Potential Stop Loss: $5.92
EYPT hit $6.17 after retesting the $5.29 Levels as we predicted hitting its 52-Wk High. The stock looks like it may be falling back...
I’m sharing this as an impromptu for this upcoming weeks Earnings regarding what stock looks like pre-R/S, being this severely damaged. I look forward to seeing how management goes forward with addressing the company’s current financial state.
- Stock at bottom of wedge = Bullish, for bounce play, especially “good” on news.
- Weekly RSI...
EyePoint Pharmaceuticals Receives $9.5 Million in Upfront Cash from Ocumension Therapeutics Under Expanded License Agreements
the expansion of their exclusive license agreements for the development and commercialization of YUTIQ® and DEXYCU® in certain Asian markets.
Ocumension has made a one-time $9.5 million payment to EyePoint for rights to commercialize both...
EYPT chart is building up for another run. Potential catalyst before year end with an sNDA for Short Duration Yutiq. accumulation has been slow and steady indicating EYPT oversold conditions.
weekly chart --> Harmonic Gartley (bounced off significant support level) and been in uptrend since.
Symmetrical Triangle/ Breakout setup has been known...
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
Long-Term pattern suggests that after previous dilution, Eyepoint's stock price went range bound for quite awhile before breaking out.
This marks potential accumulation range for anyone looking to build a position in EYPT.
Ranges make for good swing trade positions (especially 20%+ both ways) and a way to average down.
Range low/ highs, range from $1.42 -...
Eyepoint pharmaceuticals today was added to the Russell 2000 and 3000. The pharmaceutical company has alot to prove this quarter with regards to their loan with CRG, but a earnings beat would spark investor/ hedge fund investment which could give potential massive upside for EYPT and current investors.
After EYPT diluted (one of EYPT's pain points) more...
Based on the candle sticks presented, we can identify 2 key points that present opportunity in EYPT. First the “GAP” presented by the yellow highlight, when these gaps are formed and the stock starts to recover it is common for the price to rally back towards the price where the gap was created in this case roughly a bit under $2.20 ($2.11 was the lowest bid...
A brief breakdown of the channel in play, and the one following it. But this has been played numerous times over the last 2 years in our group.
EYPT to play channel 2.05 - 2.67
Bottom of channel: 2.05
Mid ranged resistance: 2.4
Top of channel & Breakout point: 2.67
Above this point we could see the next channel play 2.67 - 3.36
Bottom of this channel:...
Pumped super hard. RSI showing oversold on 1w, 1d, 4h, 3h, 2h, and 1h charts. Got rejected at resistance.
EYPT is an industry leader though, so it could correct and continue its pathway up higher.
If it breaks the support then SELL, if it breaks the resistance than...